REGN Regeneron Pharmaceuticals, Inc. - Common Stock
حول Regeneron Pharmaceuticals, Inc. - Common Stock نظرة عامة على الشركة من ويكيبيديا
ريجينيرون (الإنجليزية: Regeneron) هي شركة لصناعة الدواء والتقانة الحيوية مقرها في في تاريتاون، نيويورك. تأسست الشركة في عام 1988.
اقرأ المزيد
ريجينيرون (الإنجليزية: Regeneron) هي شركة لصناعة الدواء والتقانة الحيوية مقرها في في تاريتاون، نيويورك. تأسست الشركة في عام 1988.
ركزت الشركة على العوامل العصبية وقدرات التجدد، وتفرعت إلى دراسة كل من السيتوكين ومستقبلات كاينيز التايروسين.
== المراجع ==
المصدر: ويكيبيديا, CC BY-SA 4.0 · عرض على ويكيبيديا ↗
REGN لقطة سريعة للسهم السعر، القيمة السوقية، مكرر الربحية (P/E)، ربحية السهم (EPS)، العائد على حقوق الملكية (ROE)، نسبة الدين إلى حقوق الملكية، نطاق 52 أسبوعًا
REGN مخطط سعر السهم OHLCV يومي مع مؤشرات فنية — تحريك وتكبير وتخصيص عرضك
أداء 10 سنوات اتجاهات الإيرادات وصافي الدخل والهوامش وربحية السهم
التقييم نسب مكرر الربحية (P/E)، مكرر المبيعات (P/S)، مكرر القيمة الدفترية (P/B)، EV/EBITDA — هل السهم مرتفع السعر أم رخيص؟
الربحية هامش الربح الإجمالي والتشغيلي والصافي؛ العائد على حقوق الملكية (ROE)، العائد على الأصول (ROA)، العائد على رأس المال المستثمر (ROIC)
الصحة المالية الديون، السيولة، الملاءة المالية — قوة الميزانية العمومية
النمو نمو الإيرادات وربحية السهم وصافي الدخل: مقارنة بالعام السابق (YoY)، متوسط النمو السنوي المركب لـ 3 سنوات (3Y CAGR)، متوسط النمو السنوي المركب لـ 5 سنوات (5Y CAGR)
كفاءة رأس المال معدل دوران الأصول، معدل دوران المخزون، معدل دوران المستحقات
التوزيعات العائد، نسبة التوزيع، تاريخ توزيع الأرباح، معدل النمو السنوي المركب لمدة 5 سنوات
| تاريخ الاستحقاق | المبلغ |
|---|---|
| 18 أغسطس، 2026 | $0,9400 |
| 20 مايو، 2026 | $0,9400 |
| 20 فبراير، 2026 | $0,9400 |
| 20 نوفمبر، 2025 | $0,8800 |
| 18 أغسطس، 2025 | $0,8800 |
| 20 مايو، 2025 | $0,8800 |
| 20 فبراير، 2025 | $0,8800 |
REGN توافق الآراء التحليلي آراء المحللين الصعودية والهبوطية، السعر المستهدف لمدة 12 شهرًا، الصعود
- شراء قوي 8 21,6%
- شراء 18 48,6%
- احتفاظ 11 29,7%
- بيع 0 0,0%
- بيع قوي 0 0,0%
السعر المستهدف لمدة 12 شهرًا
27 محللين · 2026-08-19سجل الأرباح ربحية السهم الفعلية مقابل التقديرات، نسبة المفاجأة %، معدل التجاوز، تاريخ الأرباح التالي
| الفترة | EPS Actual | EPS المتوقع | المفاجأة |
|---|---|---|---|
| 30 يونيو، 2026 | $14.29 | $10.47 | 3.8% |
| 31 مارس، 2026 | $9.47 | $9.12 | 0.35% |
| 31 ديسمبر، 2025 | $11.44 | $10.83 | 0.61% |
| 30 سبتمبر، 2025 | $11.83 | $9.78 | 2.0% |
| 30 يونيو، 2025 | $12.89 | $8.61 | 4.3% |
| 31 مارس، 2025 | $8.22 | $9.00 | -0.78% |
مقارنة الأقران (الصناعة الفرعية GICS) المقاييس الرئيسية مقابل أقران القطاع
| الرمز | القيمة السوقية | P/E | الإيرادات سنويًا | هامش الربح الصافي | ROE | هامش الربح الإجمالي |
|---|---|---|---|---|---|---|
| REGN | $106.21B | 18.6 | 0.99% | 31.4% | 14.7% | — |
| ABBV | — | 96.8 | 8.6% | 6.9% | 15367.3% | — |
| AMGN | $176.35B | 23.0 | 10.0% | 21.0% | 95.9% | — |
| GILD | $152.32B | 18.1 | 2.4% | 28.9% | 40.5% | — |
| VRTX | $115.15B | 29.6 | 8.9% | 32.9% | 22.1% | — |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | — |
| RVMD | — | — | — | — | — | — |
| BIIB | $25.84B | 20.0 | 2.2% | 13.1% | 7.2% | — |
| ALNY | $52.64B | 170.7 | 65.2% | 8.5% | 60.4% | — |
الأساسيات الكاملة جميع المقاييس حسب السنة — قائمة الدخل، الميزانية العمومية، التدفق النقدي
قائمة الدخل 16
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B | $8.50B | $6.56B | $5.15B | $5.87B | $4.86B | $4.10B | $2.82B | |
| Cost of Revenue | · | · | · | · | · | · | $403M | $238M | $203M | $195M | $242M | $129M | |
| R&D Expense | $5.85B | $5.13B | $4.44B | $3.59B | $2.86B | $2.65B | $2.45B | $1.47B | $2.08B | $2.05B | $1.62B | $1.27B | |
| SG&A Expense | $2.70B | $2.95B | $2.63B | $2.12B | $1.82B | $1.35B | $1.34B | $1.13B | $1.32B | $1.18B | $839M | $519M | |
| Operating Expenses | $10.77B | $10.21B | $9.07B | $7.43B | $7.12B | $4.92B | $4.35B | $2.61B | $3.79B | $3.53B | $2.85B | $2.00B | |
| Operating Income | $3.58B | $3.99B | $4.05B | $4.74B | $8.95B | $3.58B | $2.21B | $2.53B | $2.08B | $1.33B | $1.25B | $824M | |
| Interest Expense | · | · | $73M | $59M | $57M | $57M | $30M | $28M | $25M | $7M | $14M | $37M | |
| Other Non-op | $1.70B | $844M | $225M | $179M | $436M | $291M | $250M | $47M | $24M | $6M | $-13M | $-25M | |
| Pretax Income | $5.23B | $4.78B | $4.20B | $4.86B | $9.33B | $3.81B | $2.43B | $2.55B | $2.08B | $1.33B | $1.23B | $761M | |
| Income Tax | $726M | $367M | $246M | $520M | $1.25B | $297M | $313M | $109M | $880M | $434M | $589M | $423M | |
| Net Income | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B | $3.51B | $2.12B | $2.44B | $1.20B | $896M | $636M | $338M | |
| EPS (Basic) | $43.07 | $40.90 | $37.05 | $40.51 | $76.40 | $32.65 | $19.38 | $22.65 | $11.27 | $8.55 | $6.17 | $3.36 | |
| EPS (Diluted) | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 | $10.34 | $7.70 | $5.52 | $2.98 | |
| Shares (Basic) | 104,600,000 | 107,900,000 | 106,700,000 | 107,100,000 | 105,700,000 | 107,600,000 | 109,200,000 | 107,900,000 | 106,300,000 | 104,700,000 | 103,061,000 | 100,612,000 | |
| Shares (Diluted) | 108,600,000 | 115,100,000 | 113,700,000 | 113,500,000 | 112,200,000 | 115,100,000 | 114,600,000 | 114,800,000 | 115,900,000 | 116,300,000 | 115,230,000 | 113,413,000 | |
| EBITDA | $4.12B | $4.47B | $4.47B | $5.08B | $9.23B | $3.81B | $2.42B | $2.68B | $2.23B | $1.44B | $1.33B | $891M |
الميزانية العمومية 27
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.12B | $2.49B | $2.73B | $3.11B | $2.89B | $2.19B | $1.62B | $1.47B | $813M | $535M | $809M | $649M | |
| Short-term Investments | $5.49B | $6.52B | $8.11B | $4.64B | $2.81B | $1.39B | $1.60B | $1.34B | $597M | $503M | $236M | $252M | |
| Receivables | $5.74B | $6.21B | $5.67B | $5.33B | $6.04B | $4.11B | $2.10B | $1.72B | $1.54B | $1.34B | $1.15B | $739M | |
| Inventory | $3.20B | $3.09B | $2.58B | $2.40B | $1.95B | $1.92B | $1.42B | $1.15B | $726M | $399M | $239M | $129M | |
| Prepaid Expense | $475M | $349M | $387M | $411M | $332M | $161M | $274M | $243M | $225M | $131M | $164M | $79M | |
| Current Assets | $18.02B | $18.66B | $19.48B | $15.88B | $14.01B | $9.78B | $7.69B | $6.45B | $4.33B | $3.18B | $2.92B | $2.08B | |
| PP&E (Net) | · | · | · | · | $3.48B | $3.22B | $2.89B | $2.58B | $2.36B | $2.08B | $1.59B | $974M | |
| PP&E (Gross) | · | · | · | · | · | · | $3.81B | $3.30B | $2.92B | $2.51B | $1.93B | $1.23B | |
| Accum. Depreciation | · | · | · | · | · | · | $922M | $729M | $566M | $426M | $331M | $254M | |
| Intangibles | $1.26B | $1.15B | $1.04B | $916M | $7M | · | · | · | · | · | · | · | |
| Other Non-current Assets | $1.82B | $1.14B | $444M | $336M | $216M | $168M | $145M | $127M | $78M | $20M | $6M | $3M | |
| Total Assets | $40.56B | $37.76B | $33.08B | $29.21B | $25.43B | $17.16B | $14.81B | $11.73B | $8.76B | $6.97B | $5.61B | $3.84B | |
| Accounts Payable | $939M | $790M | $607M | $589M | $564M | $476M | $418M | $218M | $178M | $879M | $644M | $483M | |
| Short-term Debt | · | · | · | · | · | · | $0 | · | · | · | · | · | |
| Current Liabilities | $4.37B | $3.94B | $3.42B | $3.14B | $3.93B | $2.70B | $2.10B | $1.44B | $1.14B | $1.24B | $811M | $655M | |
| Capital Leases | $229M | $204M | $69M | $56M | · | · | · | $708M | · | · | · | · | |
| Other Non-current Liabilities | $2.02B | $1.57B | $854M | $638M | $680M | $687M | $318M | $362M | $152M | $100M | $116M | $40M | |
| Total Liabilities | $9.30B | $8.41B | $7.11B | $6.55B | $6.67B | $6.14B | $3.72B | $2.98B | $2.62B | $2.52B | $1.95B | $1.29B | |
| Total Debt | $1.99B | $1.98B | $1.98B | $1.98B | $1.98B | $1.98B | · | · | · | · | · | · | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $108.0K | $106.0K | $102.0K | |
| Paid-in Capital | $13.99B | $12.86B | $11.35B | $9.95B | $8.09B | $6.72B | $4.43B | $3.91B | $3.51B | $3.03B | $3.10B | $2.45B | |
| Retained Earnings | $35.80B | $31.67B | $27.26B | $23.31B | $18.97B | $10.89B | $7.38B | $5.25B | $2.95B | $1.75B | $853M | $217M | |
| Treasury Stock | $18.61B | $15.17B | $12.56B | $10.35B | $8.26B | $6.61B | $740M | $396M | $316M | $316M | $306M | $170M | |
| AOCI | $78M | $-8M | $-81M | $-239M | $-26M | $29M | $21M | $-12M | $600.0K | $-13M | $9M | $52M | |
| Stockholders' Equity | $31.26B | $29.35B | $25.97B | $22.66B | $18.77B | $11.03B | $11.09B | $8.76B | $6.14B | $4.45B | $3.65B | $2.55B | |
| Liabilities + Equity | $40.56B | $37.76B | $33.08B | $29.21B | $25.43B | $17.16B | $14.81B | $11.73B | $8.76B | $6.97B | $5.61B | $3.84B | |
| Shares Outstanding | 137,600,000 | 136,000,000 | 133,100,000 | 130,400,000 | 126,200,000 | 121,500,000 | 113,300,000 | · | · | · | · | · |
التدفق النقدي 19
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $544M | $483M | $421M | $341M | $286M | $236M | $210M | $148M | $146M | $105M | $75M | $53M | |
| Stock-based Comp | $994M | $983M | $885M | $725M | $602M | $432M | $464M | $427M | $507M | $560M | $459M | $322M | |
| Deferred Tax | $-785M | $-757M | $-838M | $-746M | $-147M | $76M | $-131M | $-140M | $319M | $-360M | $-130M | $-46M | |
| Amort. of Intangibles | $179M | $129M | $92M | $38M | $0 | · | · | · | · | · | · | · | |
| Other Non-cash | $-278M | $-700M | $172M | $356M | $-1.73B | $-1.64B | $-230M | $-685M | $-863M | $273M | $291M | $86M | |
| Operating Cash Flow | $4.98B | $4.42B | $4.59B | $5.01B | $7.08B | $2.62B | $2.43B | $2.20B | $1.31B | $1.49B | $1.33B | $752M | |
| CapEx | $898M | $756M | $719M | $590M | $552M | $615M | $430M | $383M | $273M | $512M | $678M | $333M | |
| Investing Cash Flow | $-629M | $-2.47B | $-3.19B | $-3.78B | $-5.38B | $-71M | $-2.03B | $-1.46B | $-1.01B | $-1.05B | $-908M | $-421M | |
| Debt Issued | · | · | · | $0 | $0 | $1.98B | $0 | $0 | · | · | · | · | |
| Net Debt Issued | · | · | · | $0 | $0 | $1.98B | · | · | · | · | · | · | |
| Stock Issued | $636M | $1.47B | $1.15B | $1.52B | $1.67B | $2.58B | $212M | $114M | $240M | $127M | $206M | $126M | |
| Stock Repurchased | $3.44B | $2.60B | $2.23B | $2.08B | $1.65B | $5.85B | $276M | $4M | $0 | $0 | · | · | |
| Net Stock Activity | $-2.80B | $-1.14B | $-1.09B | $-563M | $27M | $-3.27B | $-64M | $110M | $240M | $127M | $206M | $126M | |
| Dividends Paid | $370M | $0 | $0 | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-3.72B | $-2.20B | $-1.79B | $-1.01B | $-1.01B | $-1.97B | $-252M | $-77M | $-24M | $-700M | $-263M | $-219M | |
| Net Change in Cash | $635M | $-249M | $-382M | $221M | $691M | $577M | $150M | $655M | $278M | $-261M | $160M | $113M | |
| Taxes Paid | $1.25B | $743M | $870M | $1.50B | $1.22B | $188M | $342M | $206M | $755M | $481M | $276M | $60M | |
| Free Cash Flow | $4.08B | $3.66B | $3.88B | $4.42B | $6.53B | $2.00B | $2.00B | $1.81B | $1.03B | $961M | $653M | $410M | |
| Levered FCF | · | · | $3.81B | $4.37B | $6.48B | $1.95B | $1.97B | $1.79B | · | · | $645M | $393M |
الربحية 7
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 24.9% | 28.1% | 30.9% | 38.9% | 55.7% | 42.1% | 28.1% | 37.8% | 35.4% | 27.4% | 30.5% | 29.7% | |
| Net Margin | 31.4% | 31.1% | 30.1% | 35.6% | 50.2% | 41.3% | 26.9% | 36.4% | 20.4% | 18.4% | 15.5% | 12.3% | |
| Pretax Margin | 36.5% | 33.7% | 32.0% | 39.9% | 58.0% | 44.8% | 30.9% | 38.0% | 35.4% | 27.4% | 29.8% | 27.5% | |
| EBITDA Margin | 28.7% | 31.5% | 34.1% | 41.7% | 57.5% | 44.9% | 30.8% | 40.0% | 37.9% | 29.5% | 32.3% | 31.6% | |
| ROA | 11.5% | 12.5% | 12.7% | 15.9% | 37.9% | 22.0% | 15.9% | 23.8% | 15.2% | 14.2% | 13.5% | 10.2% | |
| ROE | 14.7% | 15.0% | 15.5% | 19.7% | 44.8% | 33.2% | 19.6% | 29.4% | 22.6% | 22.1% | 20.5% | 15.4% | |
| ROIC | 9.3% | 11.8% | 13.6% | 17.2% | 37.3% | 25.4% | 17.4% | 27.7% | 19.5% | 20.1% | 17.8% | 14.8% |
السيولة والملاءة 5
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.1 | 4.7 | 5.7 | 5.1 | 3.6 | 3.6 | 3.7 | 4.5 | 3.8 | 2.6 | 3.6 | 3.3 | |
| Quick Ratio | 3.3 | 3.9 | 4.8 | 4.2 | 3.0 | 2.5 | 2.5 | 3.1 | 2.6 | 1.9 | 2.7 | 2.5 | |
| Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | · | · | · | · | · | · | |
| LT Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | · | · | · | · | · | · | |
| Interest Coverage | · | · | 55.4 | 79.8 | 156.1 | 62.9 | 73.2 | 89.9 | · | · | 87.9 | 22.4 |
الكفاءة 3
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.4 | 0.8 | 0.5 | 0.6 | 0.7 | 0.7 | 0.8 | 0.9 | 0.8 | |
| Inventory Turnover | · | · | · | · | · | · | · | · | 0.4 | 0.6 | 1.3 | 1.3 | |
| Receivables Turnover | 2.4 | 2.4 | 2.4 | 2.1 | 3.2 | 3.3 | 4.1 | 4.1 | 4.1 | 3.9 | 4.3 | 3.7 |
معدلات النمو 9
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 0.99% | 8.3% | 7.8% | -24.3% | 89.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.6% | -4.0% | 15.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 11.0% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 8.2% | 10.3% | -9.0% | -46.9% | 135.8% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 2.8% | -18.9% | 4.4% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 6.3% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 2.1% | 11.6% | -8.9% | -46.3% | 129.9% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 1.3% | -18.2% | 4.0% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 5.1% | · | · | · | · | · | · | · | · | · | · | · |
التقييم (آخر 12 شهرًا) 17
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B | $8.50B | $6.56B | $5.15B | $5.87B | $4.86B | $4.10B | $2.82B | |
| Net Income TTM | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B | $3.51B | $2.12B | $2.44B | $1.20B | $896M | $636M | $338M | |
| Market Cap | $106.21B | $96.88B | $116.90B | $94.08B | · | · | · | · | · | · | · | · | |
| Enterprise Value | $99.59B | $89.85B | $108.04B | $88.32B | · | · | · | · | · | · | · | · | |
| P/E | 18.6 | 18.6 | 25.3 | 18.9 | 8.8 | 15.8 | 20.3 | 17.5 | 36.4 | 47.7 | 98.3 | 137.7 | |
| P/S | 7.4 | 6.8 | 8.9 | 7.7 | · | · | · | · | · | · | · | · | |
| P/B | 3.4 | 3.3 | 4.5 | 4.2 | · | · | · | · | · | · | · | · | |
| P / Tangible Book | 3.5 | 3.4 | 4.7 | 4.3 | · | · | · | · | · | · | · | · | |
| P / Cash Flow | 21.3 | 21.9 | 25.4 | 18.8 | · | · | · | · | · | · | · | · | |
| P / FCF | 26.0 | 26.4 | 30.2 | 21.3 | · | · | · | · | · | · | · | · | |
| EV / EBITDA | 24.2 | 20.1 | 24.2 | 17.4 | · | · | · | · | · | · | · | · | |
| EV / FCF | 24.4 | 24.5 | 27.9 | 20.0 | · | · | · | · | · | · | · | · | |
| EV / Revenue | 6.9 | 6.3 | 8.2 | 7.3 | · | · | · | · | · | · | · | · | |
| Dividend Yield | 0.35% | 0.00% | 0.00% | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 5.4% | 5.4% | 4.0% | 5.3% | 11.4% | 6.3% | 4.9% | 5.7% | 2.8% | 2.1% | 1.0% | 0.73% | |
| Payout Ratio | 8.2% | · | · | · | · | · | · | · | · | · | · | · | |
| Annual Payout | $370M | $0 | $0 | · | · | · | · | · | · | · | · | · |
قائمة الدخل 15
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.29B | $3.61B | $3.88B | $3.75B | $3.68B | $3.03B | $3.79B | $3.72B | $3.55B | $3.15B | $3.43B | $3.36B | $3.16B | $3.16B | $3.41B | $2.94B | |
| R&D Expense | $1.63B | $1.54B | $1.63B | $1.48B | $1.42B | $1.33B | $1.41B | $1.27B | $1.20B | $1.25B | $1.18B | $1.08B | $1.09B | $1.10B | $1.04B | $911M | |
| SG&A Expense | $662M | $648M | $775M | $658M | $634M | $633M | $792M | $714M | $759M | $689M | $738M | $640M | $652M | $601M | $660M | $529M | |
| Operating Expenses | $3.00B | $2.96B | $3.00B | $2.73B | $2.60B | $2.44B | $2.80B | $2.54B | $2.48B | $2.39B | $2.46B | $2.25B | $2.14B | $2.22B | $2.27B | $1.71B | |
| Operating Income | $1.29B | $643M | $880M | $1.03B | $1.08B | $592M | $990M | $1.18B | $1.07B | $751M | $973M | $1.11B | $1.02B | $947M | $1.15B | $1.22B | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $16M | · | $18M | $19M | $18M | · | $15M | |
| Other Non-op | $245M | $201M | $176M | $756M | $443M | $322M | $-22M | $327M | $573M | $-35M | $193M | $18M | $85M | $-71M | $195M | $301M | |
| Pretax Income | $1.53B | $831M | $1.04B | $1.76B | $1.52B | $905M | $958M | $1.49B | $1.63B | $701M | $1.15B | $1.11B | $1.08B | $858M | $1.32B | $1.51B | |
| Income Tax | $231M | $104M | $199M | $303M | $127M | $96M | $40M | $152M | $196M | $-21M | $-12M | $103M | $114M | $40M | $128M | $194M | |
| Net Income | $1.30B | $727M | $845M | $1.46B | $1.39B | $809M | $918M | $1.34B | $1.43B | $722M | $1.16B | $1.01B | $968M | $818M | $1.20B | $1.32B | |
| EPS (Basic) | $12.62 | $6.99 | $8.16 | $14.09 | $13.24 | $7.58 | $8.55 | $12.40 | $13.25 | $6.70 | $10.88 | $9.48 | $9.05 | $7.64 | $11.18 | $12.31 | |
| EPS (Diluted) | $12.23 | $6.75 | $7.78 | $13.62 | $12.81 | $7.27 | $8.12 | $11.54 | $12.41 | $6.27 | $10.21 | $8.89 | $8.50 | $7.17 | $10.48 | $11.66 | |
| Shares (Basic) | 102,800,000 | 104,000,000 | -210,800,000 | 103,600,000 | 105,100,000 | 106,700,000 | -216,100,000 | 108,100,000 | 108,100,000 | 107,800,000 | -213,700,000 | 106,300,000 | 107,000,000 | 107,100,000 | -214,500,000 | 106,900,000 | |
| Shares (Diluted) | 106,000,000 | 107,700,000 | -218,400,000 | 107,200,000 | 108,600,000 | 111,200,000 | -231,600,000 | 116,200,000 | 115,400,000 | 115,100,000 | -227,600,000 | 113,400,000 | 113,900,000 | 114,000,000 | -226,400,000 | 112,800,000 | |
| EBITDA | $1.29B | $766M | · | $1.03B | $1.08B | $719M | · | $1.18B | $1.07B | $866M | · | $1.11B | $1.02B | $1.05B | · | $1.22B |
الميزانية العمومية 24
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.46B | $2.96B | $3.12B | $2.51B | $2.00B | $3.09B | $2.49B | $2.01B | $1.92B | $2.60B | $2.73B | $2.15B | $1.94B | $3.92B | $3.11B | $3.49B | |
| Short-term Investments | $5.54B | $5.79B | $5.49B | $5.94B | $5.47B | $5.26B | $6.52B | $7.78B | $7.89B | $7.92B | · | $7.76B | $6.99B | $5.04B | · | $3.53B | |
| Receivables | $6.57B | $5.73B | $5.74B | $5.69B | $5.61B | $5.56B | $6.21B | $6.11B | $5.72B | $5.22B | · | $5.58B | $5.12B | $5.12B | · | $5.55B | |
| Inventory | $3.08B | $3.10B | $3.20B | $3.25B | $3.21B | $3.19B | $3.09B | $3.02B | $2.87B | $2.71B | · | $2.56B | $2.51B | $2.42B | · | $2.41B | |
| Prepaid Expense | $802M | $621M | $475M | $596M | $574M | $469M | $349M | $412M | $682M | $415M | · | $575M | $366M | $406M | · | $446M | |
| Current Assets | $18.45B | $18.21B | $18.02B | $17.98B | $16.86B | $17.57B | $18.66B | $19.33B | $19.08B | $18.87B | · | $18.63B | $16.92B | $16.91B | · | $15.43B | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $3.70B | |
| Intangibles | $1.31B | $1.29B | $1.26B | $1.38B | $1.35B | $1.17B | $1.15B | $1.12B | $1.10B | $1.06B | · | $1.02B | $953M | $929M | · | $804M | |
| Other Non-current Assets | $2.31B | $2.13B | $1.82B | $1.67B | $1.54B | $1.39B | $1.14B | $1.04B | $994M | $470M | · | $410M | $393M | $350M | · | $320M | |
| Total Assets | $41.73B | $40.87B | $40.56B | $40.17B | $38.22B | $37.55B | $37.76B | $37.44B | $36.09B | $34.37B | · | $32.16B | $30.66B | $30.06B | · | $27.68B | |
| Accounts Payable | $1.16B | $1.03B | $939M | $904M | $724M | $706M | $790M | $497M | $562M | $671M | · | $537M | $547M | $600M | · | · | |
| Current Liabilities | $5.53B | $5.11B | $4.37B | $4.43B | $3.67B | $3.57B | $3.94B | $3.66B | $3.51B | $3.58B | · | $3.60B | $3.10B | $3.10B | · | $2.88B | |
| Capital Leases | · | · | $229M | · | · | · | $204M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $2.28B | $2.13B | $2.02B | $1.86B | $1.70B | $1.67B | $1.57B | $1.54B | $1.46B | $908M | · | $832M | $717M | $677M | · | $599M | |
| Total Liabilities | $10.02B | $9.45B | $9.30B | $9.21B | $8.28B | $8.16B | $8.41B | $8.12B | $7.88B | $7.38B | · | $7.26B | $6.64B | $6.56B | · | $6.24B | |
| Total Debt | $1.99B | $1.99B | · | $1.99B | $1.99B | $1.98B | · | $1.98B | $1.98B | $1.98B | · | $1.98B | $1.98B | $1.98B | · | $1.98B | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | |
| Paid-in Capital | $14.70B | $14.40B | $13.99B | $13.79B | $13.49B | $13.19B | $12.86B | $12.70B | $12.32B | $11.94B | · | $11.25B | $10.89B | $10.60B | · | $9.52B | |
| Retained Earnings | $37.62B | $36.42B | $35.80B | $35.05B | $33.68B | $32.38B | $31.67B | $30.76B | $29.41B | $27.98B | · | $26.10B | $25.09B | $24.12B | · | $22.11B | |
| Treasury Stock | $20.57B | $19.41B | $18.61B | $17.94B | $17.28B | $16.22B | $15.17B | $14.19B | $13.46B | $12.86B | · | $12.27B | $11.77B | $11.05B | · | $9.91B | |
| AOCI | $-36M | $12M | $78M | $69M | $52M | $29M | $-8M | $60M | $-70M | $-77M | · | $-177M | $-198M | $-182M | · | $-275M | |
| Stockholders' Equity | $31.71B | $31.42B | $31.26B | $30.96B | $29.94B | $29.39B | $29.35B | $29.33B | $28.21B | $26.99B | $25.97B | $24.90B | $24.02B | $23.50B | $22.66B | $21.44B | |
| Liabilities + Equity | $41.73B | $40.87B | $40.56B | $40.17B | $38.22B | $37.55B | $37.76B | $37.44B | $36.09B | $34.37B | · | $32.16B | $30.66B | $30.06B | · | $27.68B | |
| Shares Outstanding | 138,000,000 | 137,900,000 | 137,600,000 | 136,200,000 | 136,200,000 | 136,100,000 | 136,000,000 | 135,300,000 | 134,800,000 | 134,200,000 | 133,100,000 | 132,100,000 | 131,600,000 | 131,400,000 | 130,400,000 | 129,000,000 |
التدفق النقدي 15
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $124M | $123M | $145M | $137M | $135M | $127M | $126M | $122M | $121M | $114M | $113M | $105M | $103M | $100M | $100M | $93M | |
| Stock-based Comp | $243M | $257M | $249M | $237M | $252M | $256M | $304M | $225M | $223M | $230M | $240M | $204M | $202M | $239M | $232M | $166M | |
| Amort. of Intangibles | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $21M | $16M | |
| Other Non-cash | · | $-29M | · | · | · | $-146M | · | · | · | $446M | · | · | · | $212M | · | · | |
| Operating Cash Flow | $813M | $1.08B | $1.17B | $1.62B | $1.14B | $1.05B | $1.26B | $1.29B | $354M | $1.51B | $1.09B | $1.11B | $1.02B | $1.37B | $1.72B | $629M | |
| CapEx | $240M | $231M | $249M | $201M | $219M | $229M | $200M | $242M | $180M | $134M | $251M | $176M | $113M | $178M | $152M | $142M | |
| Investing Cash Flow | $-93M | $-429M | $220M | $-403M | $-1.09B | $648M | $351M | $-574M | $-557M | $-1.69B | $-66M | $-496M | $-2.39B | $-236M | $-1.86B | $192M | |
| Stock Issued | $49M | $163M | $504M | $40M | $32M | $61M | $91M | $255M | $438M | $682M | $301M | $269M | $91M | $485M | $373M | $318M | |
| Stock Repurchased | $1.17B | $794M | $672M | $664M | $1.06B | $1.04B | $973M | $735M | $604M | $291M | $289M | $546M | $689M | $711M | $431M | $935M | |
| Net Stock Activity | · | $-631M | · | · | · | $-981M | · | · | · | $391M | · | · | · | $-226M | · | · | |
| Dividends Paid | $97M | $98M | $93M | $91M | $93M | $94M | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Financing Cash Flow | $-1.22B | $-802M | $-780M | $-718M | $-1.13B | $-1.09B | $-1.14B | $-634M | $-478M | $47M | $-446M | $-407M | $-614M | $-322M | $-248M | $-725M | |
| Net Change in Cash | $-505M | $-153M | $611M | $498M | $-1.08B | $604M | $477M | $84M | $-682M | $-128M | $578M | $210M | $-1.98B | $809M | $-385M | $96M | |
| Free Cash Flow | · | $848M | · | · | · | $816M | · | · | · | $1.38B | · | · | · | $1.19B | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $1.36B | · | · | · | $1.17B | · | · |
الربحية 7
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 30.1% | 17.8% | · | 27.4% | 29.4% | 19.5% | · | 31.7% | 30.1% | 23.9% | · | 33.0% | 32.2% | 29.9% | · | 41.7% | |
| Net Margin | 30.2% | 20.2% | · | 38.9% | 37.9% | 26.7% | · | 36.0% | 40.4% | 23.0% | · | 30.0% | 30.7% | 25.9% | · | 44.8% | |
| Pretax Margin | 35.6% | 23.1% | · | 47.0% | 41.3% | 29.9% | · | 40.1% | 45.9% | 22.3% | · | 33.0% | 34.3% | 27.1% | · | 51.4% | |
| EBITDA Margin | 30.1% | 21.2% | · | 27.4% | 29.4% | 23.7% | · | 31.7% | 30.1% | 27.5% | · | 33.0% | 32.2% | 33.1% | · | 41.7% | |
| ROA | 3.2% | 1.8% | · | 3.8% | 3.8% | 2.2% | · | 3.9% | 4.3% | 2.2% | · | 3.4% | 3.4% | 2.9% | · | 5.1% | |
| ROE | 4.2% | 2.4% | · | 4.8% | 4.8% | 2.9% | · | 4.9% | 5.5% | 2.9% | · | 4.3% | 4.3% | 3.8% | · | 6.8% | |
| ROIC | 3.3% | 1.7% | · | 2.6% | 3.1% | 1.7% | · | 3.4% | 3.1% | 2.7% | · | 3.8% | 3.5% | 3.5% | · | 4.5% |
السيولة والملاءة 5
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.6 | · | 4.1 | 4.6 | 4.9 | · | 5.3 | 5.4 | 5.3 | · | 5.2 | 5.5 | 5.5 | · | 5.4 | |
| Quick Ratio | 2.6 | 2.8 | · | 3.2 | 3.6 | 3.9 | · | 4.3 | 4.4 | 4.4 | · | 4.3 | 4.5 | 4.5 | · | 4.4 | |
| Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| LT Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 46.7 | · | 62.4 | 53.8 | 52.6 | · | 80.0 |
الكفاءة 2
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 0.7 | 0.6 | · | 0.6 | 0.6 | 0.6 | · | 0.6 | 0.7 | 0.6 | · | 0.6 | 0.6 | 0.6 | · | 0.5 |
التقييم (آخر 12 شهرًا) 15
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $15.33B | $14.06B | · | $14.18B | $13.97B | $13.44B | · | $13.78B | $13.21B | $12.83B | · | $12.62B | $12.11B | $11.92B | · | $12.21B | |
| Net Income TTM | $4.88B | $4.39B | · | $5.00B | $4.97B | $4.30B | · | $4.50B | $4.13B | $3.52B | · | $4.11B | $3.95B | $3.96B | · | $4.77B | |
| Market Cap | $86.05B | $106.55B | · | $76.58B | $71.50B | $86.32B | · | $142.23B | $141.68B | $129.17B | · | $108.71B | $94.56B | $107.97B | · | $88.86B | |
| Enterprise Value | $80.04B | $99.78B | · | $70.12B | $66.02B | $79.95B | · | $134.42B | $133.85B | $120.63B | · | $100.78B | $87.61B | $100.99B | · | $83.82B | |
| P/E | 13.7 | 19.1 | · | 12.4 | 11.9 | 16.9 | · | 26.9 | 29.1 | 31.2 | · | 22.7 | 20.6 | 23.5 | · | 16.4 | |
| P/S | 5.6 | 7.6 | · | 5.4 | 5.1 | 6.4 | · | 10.3 | 10.7 | 10.1 | · | 8.6 | 7.8 | 9.1 | · | 7.3 | |
| P/B | 2.7 | 3.4 | · | 2.5 | 2.4 | 2.9 | · | 4.9 | 5.0 | 4.8 | · | 4.4 | 3.9 | 4.6 | · | 4.1 | |
| P / Tangible Book | 2.8 | 3.5 | · | 2.6 | 2.5 | 3.1 | · | 5.0 | 5.2 | 5.0 | · | 4.6 | 4.1 | 4.8 | · | 4.3 | |
| P / Cash Flow | · | 98.8 | · | · | · | 82.6 | · | · | · | 85.4 | · | · | · | 78.9 | · | · | |
| P / FCF | · | 125.6 | · | · | · | 105.8 | · | · | · | 93.7 | · | · | · | 90.8 | · | · | |
| EV / EBITDA | 61.9 | 130.2 | · | 68.3 | 61.2 | 111.3 | · | 114.0 | 125.1 | 139.4 | · | 90.7 | 86.2 | 96.5 | · | 68.5 | |
| EV / FCF | · | 117.6 | · | · | · | 98.0 | · | · | · | 87.5 | · | · | · | 84.9 | · | · | |
| EV / Revenue | 5.2 | 7.1 | · | 4.9 | 4.7 | 5.9 | · | 9.8 | 10.1 | 9.4 | · | 8.0 | 7.2 | 8.5 | · | 6.9 | |
| Earnings Yield | 7.3% | 5.2% | · | 8.1% | 8.4% | 5.9% | · | 3.7% | 3.4% | 3.2% | · | 4.4% | 4.8% | 4.2% | · | 6.1% | |
| Payout Ratio | · | 13.5% | · | · | · | 11.6% | · | · | · | · | · | · | · | · | · | · |
القوائم المالية قائمة الدخل، الميزانية العمومية، التدفقات النقدية — سنويًا، آخر 5 سنوات
قائمة الدخل
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| الإيرادات | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B |
| هامش الربح التشغيلي % | 24.9% | 28.1% | 30.9% | 38.9% | 55.7% |
| صافي الدخل | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B |
| EPS المخفف | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 |
الميزانية العمومية
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| الدين / حقوق الملكية | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| النسبة الحالية | 4.1 | 4.7 | 5.7 | 5.1 | 3.6 |
| النسبة السريعة | 3.3 | 3.9 | 4.8 | 4.2 | 3.0 |
التدفق النقدي
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| التدفق النقدي الحر | $4.08B | $3.66B | $3.88B | $4.42B | $6.53B |
آخر الأخبار أحدث العناوين التي تذكر هذه الشركة
- ممتلكات FDG توحي بإمكانية تحقيق مكاسب بنسبة 20%
- صندوق iShares MSCI USA Min Vol Factor ETF يشهد تدفقات خارجية كبيرة
- تعلن شركة ريجينيرون للأدوية (REGN) عن تعاون مع شركة Telix Pharmaceuticals Limited
- نظرة عامة على الأرباح: ما يمكن توقعه من تقرير شركة Regeneron Pharmaceuticals
- تتعاون شركة Regeneron Pharma مع شركة Telix Pharma لتطوير علاجات إشعاعية مشتركة
- جيم كرامر عن ريجينيرون (REGN): 'أعتقد أن السهم ينطلق هنا'
- تلیکس و ريجينرون تتعاونان لتعزيز علاجات الأدوية المشعة من الجيل التالي
- فورميكون تؤمن توقيت إطلاق FYB203 في أوروبا بعد تسوية Regeneron و Bayer
- هل سهم Regeneron Pharmaceuticals, Inc. (REGN) سهم جيد للشراء؟
إشارات التداول إشارات شراء/بيع حديثة مع سعر الدخول ونسبة المخاطرة/المكافأة
مقاييسي قائمة المراقبة الشخصية الخاصة بك — صفوف مختارة من الأساسيات الكاملة
اختر المقاييس التي تهمك — انقر فوق علامة ➕ بجوار أي صف في الأساسيات الكاملة أعلاه.
يتم حفظ اختيارك ويتبعك عبر جميع الأسهم.
الملاك المؤسسيون (13F) 1481 مقدمي إقرار · $34.8B إجمالي · حتى تاريخ 30 يونيو، 2026
المؤسسات التي تبلغ عن حيازتها لهذا السهم في نموذج SEC 13F ربع السنوي الخاص بها. المراكز الطويلة فقط؛ قد يظهر مقدم واحد مرتين لأرجل خيارات منفصلة. الأرجل الكبيرة المتعاكسة من خيارات البيع/الشراء تعكس عادةً صناعة السوق أو المخزون المتحوط، وليس القناعة الاتجاهية.
| مراكز جديدة | المراكز الخارجة | زيادة | انخفض | صافي التغير في الأسهم |
|---|---|---|---|---|
| 124 (-35 مقابل الربع السابق) | 162 (+63 مقابل الربع السابق) | 481 (-68 مقابل الربع السابق) | 526 (+45 مقابل الربع السابق) | +9.2M |
مقارنة بـ Q1 2026. المواعيد النهائية لتقديم إقرارات نموذج 13F لهيئة الأوراق المالية والبورصات (SEC) هي في غضون 45 يومًا من نهاية الربع بالإضافة إلى فترة سماح قصيرة للمقدمين المتأخرين — يتم تخطي الأرباع التي لا تزال ضمن هذه النافذة لصالح أحدث زوج تم الإبلاغ عنه بالكامل.
| مؤسسة | القيمة | الأسهم | % من 13F المتتبعة | النوع |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $4133919926 | 6629759 | 11,89% | الأسهم |
| Dodge & Cox | $3037348765 | 4871137 | 8,73% | الأسهم |
| STATE STREET CORP | $3014621356 | 4834688 | 8,67% | الأسهم |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1979934668 | 3175313 | 5,69% | الأسهم |
| GEODE CAPITAL MANAGEMENT, LLC | $1427303015 | 2297074 | 4,10% | الأسهم |
| LOOMIS SAYLES & CO L P | $1014501372 | 1627003 | 2,92% | الأسهم |
| PeakShares LLC | $975217000 | 1564 | 2,80% | الأسهم |
| WELLINGTON MANAGEMENT GROUP LLP | $763126911 | 1223862 | 2,19% | الأسهم |
| NORGES BANK | $731292700 | 1172808 | 2,10% | الأسهم |
| Capital World Investors | $508138359 | 814925 | 1,46% | الأسهم |
| TWO SIGMA ADVISERS, LP | $466626290 | 604540 | 1,34% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $432674406 | 693900 | 1,24% | عقد خيار البيع |
| TWO SIGMA INVESTMENTS, LP | $409119559 | 656124 | 1,18% | الأسهم |
| GOLDMAN SACHS GROUP INC | $392576914 | 629594 | 1,13% | الأسهم |
| VANGUARD FIDUCIARY TRUST CO | $351496357 | 563711 | 1,01% | الأسهم |
| FIRST TRUST ADVISORS LP | $341158711 | 547132 | 0,98% | الأسهم |
| DIMENSIONAL FUND ADVISORS LP | $299532285 | 480373 | 0,86% | الأسهم |
| Robeco Institutional Asset Management B.V. | $287203770 | 460602 | 0,83% | الأسهم |
| NEUBERGER BERMAN GROUP LLC | $259935179 | 416870 | 0,75% | الأسهم |
| BNP PARIBAS FINANCIAL MARKETS | $249320598 | 399847 | 0,72% | الأسهم |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $245478345 | 393685 | 0,71% | الأسهم |
| National Pension Service | $236829845 | 379815 | 0,68% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $236259306 | 378900 | 0,68% | عقد خيار الشراء |
| ALLIANCEBERNSTEIN L.P. | $225872032 | 292338 | 0,65% | الأسهم |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $220714454 | 353970 | 0,63% | الأسهم |
| BlackRock, Inc. | $207677479 | 333062 | 0,60% | الأسهم |
| JANE STREET GROUP, LLC | $198659844 | 318600 | 0,57% | عقد خيار الشراء |
| Swiss National Bank | $182709691 | 293020 | 0,53% | الأسهم |
| Sumitomo Mitsui Trust Group, Inc. | $175962364 | 282199 | 0,51% | الأسهم |
| BANK OF AMERICA CORP /DE/ | $171791505 | 275510 | 0,49% | الأسهم |
| CITADEL ADVISORS LLC | $169166402 | 271300 | 0,49% | عقد خيار الشراء |
| FIL Ltd | $165543635 | 265490 | 0,48% | الأسهم |
| CITADEL ADVISORS LLC | $164988684 | 264600 | 0,47% | عقد خيار البيع |
| FMR LLC | $162474852 | 260568 | 0,47% | الأسهم |
| TD Asset Management Inc | $161694522 | 259317 | 0,46% | الأسهم |
| Mitsubishi UFJ Asset Management Co., Ltd. | $160530373 | 257450 | 0,46% | الأسهم |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $159939881 | 256503 | 0,46% | الأسهم |
| Nuveen, LLC | $158965911 | 254941 | 0,46% | الأسهم |
| Caisse de depot et placement du Quebec | $156264112 | 250608 | 0,45% | الأسهم |
| Assenagon Asset Management S.A. | $152721782 | 244927 | 0,44% | الأسهم |
| Vanguard Global Advisers, LLC | $141371483 | 226724 | 0,41% | الأسهم |
| California Public Employees Retirement System | $139840692 | 224269 | 0,40% | الأسهم |
| Qube Research & Technologies Ltd | $138180829 | 221607 | 0,40% | الأسهم |
| Legal & General Group Plc | $134385341 | 215520 | 0,39% | الأسهم |
| CANADA PENSION PLAN INVESTMENT BOARD | $130887905 | 209911 | 0,38% | الأسهم |
| Squarepoint Ops LLC | $123814467 | 198567 | 0,36% | الأسهم |
| VANGUARD ASSET MANAGEMENT, Ltd | $123317506 | 197770 | 0,35% | الأسهم |
| Candriam S.C.A. | $121893176 | 195674 | 0,35% | الأسهم |
| MCDONALD CAPITAL INVESTORS INC/CA | $120366915 | 193038 | 0,35% | الأسهم |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $119141861 | 154201 | 0,34% | الأسهم |
| Swedbank AB | $118377821 | 189848 | 0,34% | الأسهم |
| Carmignac Gestion | $113826706 | 182507 | 0,33% | الأسهم |
| BANK OF NOVA SCOTIA | $113300959 | 181706 | 0,33% | الأسهم |
| JANE STREET GROUP, LLC | $112548970 | 180500 | 0,32% | عقد خيار البيع |
| BARCLAYS PLC | $111306254 | 178507 | 0,32% | الأسهم |
| PANAGORA ASSET MANAGEMENT INC | $109300950 | 175291 | 0,31% | الأسهم |
| GOLDMAN SACHS GROUP INC | $106687694 | 171100 | 0,31% | عقد خيار الشراء |
| MILLENNIUM MANAGEMENT LLC | $102958925 | 165120 | 0,30% | الأسهم |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $102237489 | 163963 | 0,29% | الأسهم |
| Bronte Capital Management Pty Ltd. | $101398828 | 162618 | 0,29% | الأسهم |
| NORDEA INVESTMENT MANAGEMENT AB | $100247789 | 160258 | 0,29% | الأسهم |
| RAYMOND JAMES FINANCIAL INC | $99201835 | 159095 | 0,29% | الأسهم |
| RHUMBLINE ADVISERS | $98390781 | 157794 | 0,28% | الأسهم |
| Pictet Asset Management Holding SA | $96459212 | 153500 | 0,28% | الأسهم |
| RENAISSANCE TECHNOLOGIES LLC | $92422346 | 148222 | 0,27% | الأسهم |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $92259602 | 147961 | 0,27% | الأسهم |
| AMERIPRISE FINANCIAL INC | $90305429 | 144827 | 0,26% | الأسهم |
| MACKENZIE FINANCIAL CORP | $84666132 | 135783 | 0,24% | الأسهم |
| PRUDENTIAL FINANCIAL INC | $81380076 | 130513 | 0,23% | الأسهم |
| Retirement Systems of Alabama | $79731436 | 127869 | 0,23% | الأسهم |
| MARSHALL WACE, LLP | $79189580 | 127000 | 0,23% | عقد خيار البيع |
| Sound Shore Management Inc /CT/ | $79185839 | 126994 | 0,23% | الأسهم |
| VICTORY CAPITAL MANAGEMENT INC | $78779916 | 126343 | 0,23% | الأسهم |
| ProShare Advisors LLC | $74350910 | 119240 | 0,21% | الأسهم |
| NEW YORK STATE COMMON RETIREMENT FUND | $69443026 | 111369 | 0,20% | الأسهم |
| ENVESTNET ASSET MANAGEMENT INC | $68488193 | 109838 | 0,20% | الأسهم |
| Gotham Asset Management, LLC | $65574584 | 105165 | 0,19% | الأسهم |
| Harvest Portfolios Group Inc. | $65232261 | 104616 | 0,19% | الأسهم |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $62737149 | 100286 | 0,18% | الأسهم |
| Mariner, LLC | $61632002 | 98826 | 0,18% | الأسهم |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $61471693 | 98585 | 0,18% | الأسهم |
| PARNASSUS INVESTMENTS, LLC | $59471998 | 95378 | 0,17% | الأسهم |
| Davern Capital Partners, LP | $57764746 | 92640 | 0,17% | الأسهم |
| AVIVA PLC | $57045180 | 91486 | 0,16% | الأسهم |
| PFA Pension, Forsikringsaktieselskab | $56561245 | 90710 | 0,16% | الأسهم |
| ARMISTICE CAPITAL, LLC | $55999504 | 89809 | 0,16% | الأسهم |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $54996852 | 88201 | 0,16% | الأسهم |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $52429737 | 84084 | 0,15% | الأسهم |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $52158497 | 83649 | 0,15% | الأسهم |
| ROYAL BANK OF CANADA | $51450000 | 82513 | 0,15% | الأسهم |
| CWM, LLC | $51303491 | 66400 | 0,15% | الأسهم |
| PINNACLE ASSOCIATES LTD | $50660926 | 81247 | 0,15% | الأسهم |
| GROUPAMA ASSET MANAGMENT | $49128285 | 77940 | 0,14% | الأسهم |
| NEOS Investment Management LLC | $48213359 | 77322 | 0,14% | الأسهم |
| CAPITOLIS LIQUID GLOBAL MARKETS LLC | $46765500 | 75000 | 0,13% | الأسهم |
| Korea Investment CORP | $46737441 | 74955 | 0,13% | الأسهم |
| Grantham, Mayo, Van Otterloo & Co. LLC | $46266668 | 74200 | 0,13% | الأسهم |
| WOLVERINE TRADING, LLC | $45925425 | 81900 | 0,13% | عقد خيار الشراء |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $45875500 | 59375 | 0,13% | الأسهم |
| Woodline Partners LP | $45265886 | 72595 | 0,13% | الأسهم |
المطلعون على الشركة 39 من المطلعين · مسؤولون 3 · مديرون 7
| مطلع | الدور | آخر نشاط | الأسهم المملوكة | مشتريات 12 شهرًا | مبيعات 12 شهرًا | صافي 12 شهرًا |
|---|---|---|---|---|---|---|
| Leonard S Schleifer | Bd. Co-Chair, President & CEO | 31 ديسمبر، 2025 M | 214523 | 0 | 0 | $0 |
| Christopher R. Fenimore | SVP Controller | 20 أغسطس، 2021 F | 19020 | 0 | 0 | $0 |
| Van Plew Daniel P | EVP & General Mgr Industrial O | 20 أغسطس، 2020 M | 47110 | 0 | 0 | $0 |
| Arthur F Ryan | مدير | 2 يوليو، 2026 S | 17303 | 0 | 48 | $-434683 |
| Anthony N Coles | مدير | 2 يناير، 2026 A | 1714 | 0 | 0 | $0 |
| Christine A Poon | مدير | 2 يناير، 2026 A | 5219 | 0 | 6 | $-4252745 |
| Michael S Brown | مدير | 2 يناير، 2026 A | 1703 | 0 | 0 | $0 |
| David P Schenkein | مدير | 8 سبتمبر، 2023 A | 240 | 0 | 0 | $0 |
| Craig B. Thompson | مدير | 3 أكتوبر، 2022 A | 279 | 0 | 0 | $0 |
| REGENERON PHARMACEUTICALS, INC. | مالك 10% | 17 فبراير، 2021 C | 2097314 | 0 | 0 | $0 |
| Sanofi | مالك 10% | 9 يونيو، 2020 S | 279766 | 0 | 0 | $0 |
| Pharma Ag Novartis | مالك 10% | 8 نوفمبر، 2005 S | — | 0 | 0 | $0 |
| Kathryn Guarini | — | 10 أغسطس، 2026 M | 603 | 0 | 1 | $-320000 |
| Huda Y Zoghbi | — | 10 أغسطس، 2026 M | 1703 | 0 | 1 | $-640000 |
| Joseph L Goldstein | — | 2 يناير، 2026 A | 6703 | 0 | 0 | $0 |
| George L Sing | — | 2 يناير، 2026 A | 31007 | 0 | 0 | $0 |
| George Yancopoulos | — | 31 ديسمبر، 2025 M | 310460 | 0 | 0 | $0 |
| Joseph J Larosa | — | 5 ديسمبر، 2025 A | 29517 | 0 | 0 | $0 |
| Marc Tessier-Lavigne | — | 9 ديسمبر، 2021 M | 2078 | 0 | 0 | $0 |
| Marion Mccourt | — | 7 يونيو، 2021 M | 17038 | 0 | 0 | $0 |
| Andrew J Murphy | — | 9 ديسمبر، 2020 A | 57350 | 0 | 0 | $0 |
| Robert E Landry | — | 9 ديسمبر، 2020 A | 25903 | 0 | 0 | $0 |
| Neil Stahl | — | 9 ديسمبر، 2020 A | 24715 | 0 | 0 | $0 |
| Bonnie L Bassler | — | 19 يونيو، 2020 M | 643 | 0 | 0 | $0 |
| VAGELOS P ROY | — | 16 ديسمبر، 2019 I | 2200 | 0 | 0 | $0 |
| Charles A Baker | — | 2 يناير، 2018 A | 9000 | 0 | 0 | $0 |
| Robert J Terifay | — | 12 ديسمبر، 2017 A | 23293 | 0 | 0 | $0 |
| Michael S Aberman | — | 16 ديسمبر، 2016 A | 16498 | 0 | 0 | $0 |
| Peter Powchik | — | 16 ديسمبر، 2016 A | 2459 | 0 | 0 | $0 |
| Douglas S Mccorkle | — | 29 ديسمبر، 2015 M | 6866 | 0 | 0 | $0 |
| Alfred G Gilman | — | 6 أغسطس، 2015 M | 8912 | 0 | 0 | $0 |
| Robert Alexander Ingram | — | 22 مايو، 2015 M | 1500 | 0 | 0 | $0 |
| Murray A Goldberg | — | 16 ديسمبر، 2014 A | 64436 | 0 | 0 | $0 |
| Eric M Shooter | — | 12 فبراير، 2014 M | 0 | 0 | 0 | $0 |
| William Roberts | — | 18 سبتمبر، 2013 M | 13447 | 0 | 0 | $0 |
| Stuart Kolinski | — | 3 يونيو، 2010 M | 16329 | 0 | 0 | $0 |
| Peter Dworkin | — | 18 ديسمبر، 2009 A | — | 0 | 0 | $0 |
| Randall Rupp | — | 13 إبريل، 2007 M | 3983 | 0 | 0 | $0 |
| Hans Peter Guler | — | 8 أكتوبر، 2004 M | 10530 | 0 | 0 | $0 |
المطلعون من إيداعات SEC Form 3/4/5؛ صافي = سوق مفتوح فقط
الناشطون والمالكون بنسبة 5%+ 2 حيازتان
المستثمرون الذين قدموا الجدول الزمني 13D لدى هيئة الأوراق المالية والبورصات — ملكية مستفيدة تزيد عن 5% مع نية التأثير على المُصدر (حصص الناشطين، حملات مجلس الإدارة، الاندماج والاستحواذ). يعرض كل صف أحدث حالة معروفة لمركز مقدم الطلب هذا.
| مقدم | مقدم | حصة | الحالة | الغرض | إيداع |
|---|---|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC., SYMPHONY ACQUISITION SUB, INC. ×2 إيداعات | 27 سبتمبر، 2023 | — | إيداع أولي | — | SEC |
| Sanofi ×17 إيداعات | 17 يونيو، 2020 | — | إيداع أولي | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ملكية صناديق المؤشرات المتداولة محتفظ بها بواسطة 237 صناديق مؤشرات متداولة
الوزن يعكس فقط ممتلكات الأسهم المباشرة (N-PORT)؛ قد تحتفظ الصناديق المضاعفة أو القائمة على المشتقات بتعرض إضافي للمقايضة غير معروض.
| صندوق | الوزن | الوحدات | حتى تاريخ | المصدر |
|---|---|---|---|---|
| TBXU · Direxion Shares ETF Trust | 8,55% | 357 NS | 30 إبريل، 2026 | N-PORT |
| IBB · iShares Trust | 6,00% | 740981 SH | 8 أغسطس، 2026 | يومي |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 5,51% | 5609 SH | 8 أغسطس، 2026 | يومي |
| PBE · Invesco Exchange-Traded Fund Trust | 5,42% | 25033 SH | 8 أغسطس، 2026 | يومي |
| IDNA · iShares Trust | 4,25% | 10887 SH | 8 أغسطس، 2026 | يومي |
| BIB · ProShares Trust | 3,21% | 3840 NS | 31 مايو، 2026 | N-PORT |
| PJP · Invesco Exchange-Traded Fund Trust | 3,14% | 20280 SH | 8 أغسطس، 2026 | يومي |
| QQQA · ProShares Trust | 2,93% | 2168 NS | 31 مايو، 2026 | N-PORT |
| AGNG · Global X Funds | 2,48% | 3299 NS | 31 مايو، 2026 | N-PORT |
| SDG · iShares Trust | 2,28% | 5119 SH | 8 أغسطس، 2026 | يومي |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 2,19% | 344 NS | 30 إبريل، 2026 | N-PORT |
| QQQG · Pacer Funds Trust | 2,18% | 348 NS | 30 إبريل، 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,98% | 24491 NS | 30 إبريل، 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,98% | 19712 SH | 8 أغسطس، 2026 | يومي |
| SGLC · RBB Fund, Inc. | 1,87% | 5922 NS | 31 مايو، 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,78% | 1346 NS | 30 إبريل، 2026 | N-PORT |
| HRTS · Tema ETF Trust | 1,67% | 1408 NS | 31 مايو، 2026 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 1,64% | 37398 SH | 8 أغسطس، 2026 | يومي |
| TECB · iShares Trust | 1,60% | 9957 SH | 8 أغسطس، 2026 | يومي |
| BBP · ETFis Series Trust I | 1,52% | 1276 NS | 30 إبريل، 2026 | N-PORT |
| QNXT · iShares Trust | 1,48% | 539 SH | 8 أغسطس، 2026 | يومي |
| RILA · Spinnaker ETF Series | 1,44% | 854 NS | 30 إبريل، 2026 | N-PORT |
| COWG · Pacer Funds Trust | 1,40% | 43095 NS | 30 إبريل، 2026 | N-PORT |
| FLAG · Global X Funds | 1,29% | 30 NS | 30 إبريل، 2026 | N-PORT |
| IYH · iShares Trust | 1,27% | 60521 SH | 8 أغسطس، 2026 | يومي |
| NUGO · Nushares ETF Trust | 1,27% | 50872 NS | 30 إبريل، 2026 | N-PORT |
| GMOV · GMO ETF Trust | 1,19% | 1758 NS | 31 مايو، 2026 | N-PORT |
| FCPI · FIDELITY COVINGTON TRUST | 1,19% | 4569 NS | 30 إبريل، 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 1,18% | 47616 NS | 30 إبريل، 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 1,17% | 299615 NS | 30 إبريل، 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 1,16% | 770 NS | 30 إبريل، 2026 | N-PORT |
| IMCV · iShares Trust | 1,08% | 16108 SH | 8 أغسطس، 2026 | يومي |
| CURE · Direxion Shares ETF Trust | 1,03% | 2010 NS | 30 إبريل، 2026 | N-PORT |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0,99% | 444 NS | 30 إبريل، 2026 | N-PORT |
| CVAR · ETF Opportunities Trust | 0,99% | 540 NS | 30 إبريل، 2026 | N-PORT |
| IXJ · iShares Trust | 0,98% | 52534 SH | 8 أغسطس، 2026 | يومي |
| VHT · VANGUARD WORLD FUND | 0,95% | 312338 SH | 8 أغسطس، 2026 | يومي |
| FLCV · Federated Hermes ETF Trust | 0,90% | 1412 NS | 31 مايو، 2026 | N-PORT |
| RXL · ProShares Trust | 0,90% | 1051 NS | 31 مايو، 2026 | N-PORT |
| QQQE · Direxion Shares ETF Trust | 0,87% | 14942 NS | 30 إبريل، 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,85% | 6267 NS | 30 إبريل، 2026 | N-PORT |
| SPXD · DBX ETF Trust | 0,79% | 87 NS | 31 مايو، 2026 | N-PORT |
| TAX · EA Series Trust | 0,78% | 324 NS | 29 مايو، 2026 | N-PORT |
| QIDX · Spinnaker ETF Series | 0,77% | 419 NS | 30 إبريل، 2026 | N-PORT |
| JOET · Virtus ETF Trust II | 0,75% | 2512 NS | 30 إبريل، 2026 | N-PORT |
| CANC · Tema ETF Trust | 0,75% | 2138 NS | 31 مايو، 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,73% | 8277 SH | 8 أغسطس، 2026 | يومي |
| FLRG · FIDELITY COVINGTON TRUST | 0,72% | 2871 NS | 30 إبريل، 2026 | N-PORT |
| PEXL · Pacer Funds Trust | 0,69% | 448 NS | 30 إبريل، 2026 | N-PORT |
| FLCC · Federated Hermes ETF Trust | 0,69% | 1360 NS | 31 مايو، 2026 | N-PORT |